CN103619338B - 鼻内苯并二氮杂卓药物组合物 - Google Patents

鼻内苯并二氮杂卓药物组合物 Download PDF

Info

Publication number
CN103619338B
CN103619338B CN201280017015.8A CN201280017015A CN103619338B CN 103619338 B CN103619338 B CN 103619338B CN 201280017015 A CN201280017015 A CN 201280017015A CN 103619338 B CN103619338 B CN 103619338B
Authority
CN
China
Prior art keywords
weight
diazepam
formulation
dzns
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280017015.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103619338A (zh
Inventor
加里·布里姆
摩西·A·凯雷拉
白洺基
赵载勳
张惠真
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Neuronex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd, Neuronex Inc filed Critical SK Biopharmaceuticals Co Ltd
Publication of CN103619338A publication Critical patent/CN103619338A/zh
Application granted granted Critical
Publication of CN103619338B publication Critical patent/CN103619338B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201280017015.8A 2011-03-31 2012-03-30 鼻内苯并二氮杂卓药物组合物 Active CN103619338B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161469940P 2011-03-31 2011-03-31
US61/469,940 2011-03-31
PCT/US2012/031453 WO2012135619A2 (en) 2011-03-31 2012-03-30 Intranasal benzodiazepine pharmaceutical compositions

Publications (2)

Publication Number Publication Date
CN103619338A CN103619338A (zh) 2014-03-05
CN103619338B true CN103619338B (zh) 2016-06-22

Family

ID=46928023

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280017015.8A Active CN103619338B (zh) 2011-03-31 2012-03-30 鼻内苯并二氮杂卓药物组合物

Country Status (15)

Country Link
US (3) US20120252793A1 (enExample)
EP (1) EP2691100A4 (enExample)
JP (1) JP2014509655A (enExample)
KR (1) KR20140029426A (enExample)
CN (1) CN103619338B (enExample)
AR (1) AR085927A1 (enExample)
AU (1) AU2012236334B2 (enExample)
BR (1) BR112013024968A2 (enExample)
CA (1) CA2831308A1 (enExample)
MX (1) MX357800B (enExample)
PH (2) PH12013501915A1 (enExample)
RU (2) RU2018135967A (enExample)
SG (2) SG193958A1 (enExample)
TW (1) TWI601532B (enExample)
WO (1) WO2012135619A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
JP5929800B2 (ja) * 2012-04-03 2016-06-08 コニカミノルタ株式会社 定着液および画像形成方法
AU2018275686B2 (en) * 2017-06-02 2024-02-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
US11278492B2 (en) 2018-01-05 2022-03-22 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
WO2019182745A1 (en) * 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
MX2020013192A (es) 2018-06-04 2021-08-16 Arcutis Inc Metodo y formulacion para mejorar el tiempo de retraso de penetracion en la piel de roflumilast.
CN111529489A (zh) * 2020-04-17 2020-08-14 山东省药学科学院 一种含有地西泮的鼻腔喷雾剂
EP4255393B1 (en) 2020-12-04 2025-05-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having antifungal properties
MX2024008192A (es) 2021-12-28 2024-09-10 Arcutis Biotherapeutics Inc Espumas en aerosol de roflumilast topico.
JP2025530005A (ja) 2022-09-15 2025-09-09 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト及び大量のロフルミラストを溶解可能な溶媒の医薬組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009139589A2 (en) * 2008-05-14 2009-11-19 Sk Holdings Co., Ltd. Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE229817T1 (de) * 1996-10-24 2003-01-15 Alza Corp Penetrationsfördernde substanzen für die transdermale verabreichung von wirkstoffen, vorrichtungen und verfahren zur herstellung
EP1196156B1 (en) * 1999-07-26 2008-04-30 SK Holdings Co., Ltd. Transnasal anticonvulsive compositions
DK1539285T4 (da) * 2002-09-03 2012-01-02 Pharmacure Health Care Ab Næsesprayer
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
US7745430B2 (en) * 2006-11-15 2010-06-29 Sk Holdings Co., Ltd. Transnasal anticonvulsive pharmaceutical composition
US8946208B2 (en) * 2007-08-31 2015-02-03 Archimedes Development Limited Non-aqueous pharmaceutical composition
WO2011034920A1 (en) * 2009-09-16 2011-03-24 Allergan, Inc. Compositions and methods for treating seizure disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009139589A2 (en) * 2008-05-14 2009-11-19 Sk Holdings Co., Ltd. Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant

Also Published As

Publication number Publication date
KR20140029426A (ko) 2014-03-10
SG193958A1 (en) 2013-11-29
US20140128381A1 (en) 2014-05-08
RU2013148120A (ru) 2015-05-10
US20170151258A1 (en) 2017-06-01
BR112013024968A2 (pt) 2016-12-20
PH12017501688A1 (en) 2018-09-10
CA2831308A1 (en) 2012-10-04
JP2014509655A (ja) 2014-04-21
MX357800B (es) 2018-07-25
AU2012236334A1 (en) 2013-10-10
AU2012236334B2 (en) 2017-02-16
CN103619338A (zh) 2014-03-05
HK1195252A1 (zh) 2014-11-07
EP2691100A4 (en) 2014-09-24
WO2012135619A3 (en) 2012-11-22
MX2013011336A (es) 2013-12-16
AR085927A1 (es) 2013-11-06
RU2018135967A (ru) 2018-11-14
US20120252793A1 (en) 2012-10-04
SG10201602176RA (en) 2016-04-28
TWI601532B (zh) 2017-10-11
TW201302204A (zh) 2013-01-16
EP2691100A2 (en) 2014-02-05
PH12013501915A1 (en) 2019-11-29
WO2012135619A2 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
CN103619338B (zh) 鼻内苯并二氮杂卓药物组合物
US8609651B2 (en) Pharmaceutical compositions of benzodiazepines and method of use thereof
US20220273672A1 (en) Orally inhaled and nasal benzodiazepines
US20160199296A1 (en) Nasal formulations of benzodiazepine
US20250302741A1 (en) Intranasal olanzapine formulations and methods of their use
HK1195252B (en) Intranasal benzodiazepine pharmaceutical compositions
US20250352554A1 (en) Intranasal olanzapine formulations and methods of their use
WO2025176701A1 (en) Novel pediatric composition of nasal dexmedetomidine
HK40005168A (en) Orally inhaled and nasal benzodiazepines
HK40005168B (en) Orally inhaled and nasal benzodiazepines

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1195252

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1195252

Country of ref document: HK

TR01 Transfer of patent right

Effective date of registration: 20180207

Address after: Seoul, South Kerean

Patentee after: SK Biopharmaceuticals Co., Ltd.

Address before: American New York

Co-patentee before: SK Biopharmaceuticals Co., Ltd.

Patentee before: NEURONEX, INC.

TR01 Transfer of patent right